NCT06055439View on ClinicalTrials.gov

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Neuroendocrine TumorsColorectal CancerGastric Cancer
Interventions
BIOLOGICAL

CHM-2101 CAR-T cells

Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR)-positive T cells

Trial Locations (4)

19104

RECRUITING

University of Pennsylvania, Philadelphia

30322

RECRUITING

Emory University, Atlanta

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

60637

RECRUITING

University of Chicago, Chicago

Sponsors
All Listed Sponsors
lead

Chimeric Therapeutics

INDUSTRY